tsla

FDA Panel Votes in Favor of ACADIA Pharmaceuticals Inc. (ACAD)

An FDA panel ruled favorably on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Mar 29, 2016 at 3:20 PM
facebook X logo linkedin


A Food and Drug Administration (FDA) panel voted 12-2 this afternoon that ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Parkinson's disease psychosis (PDP) drug, Nuplazid, has been shown to be substantially effective. This likely puts the drug on a path toward FDA approval. 

ACAD has been halted all day Tuesday as Wall Street awaited the FDA panel's decision. The shares settled last night at $23.81 after gapping higher on Monday, but remain 33% lower for 2016. 

This will likely be bad news for ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) short sellers, though. Specifically, the more than 17 million ACAD shares sold short would take upwards of eight trading days to buy back, at the stock's average daily volume. In light of today's FDA news, a rush to cover by some of the weaker bearish hands could result in tailwinds for ACAD shares. 

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.

 

Two High-Octane Trade Ideas. One Simple Goal: Intraday Profits.

Dynamite Day Trading Signals delivers two same-day options trades every week — powered by proprietary intraday analysis and 43+ years of trading expertise.

But this isn’t just another stream of alerts.

It’s a structured plan with clear entry and exit points – designed for traders who want to act fast, trade smart, and wrap up gains before the closing bell.

No guesswork. No overnight exposure – Just two well-researched setups per week — whether you prefer buying premium or selling it.

And the results speak for themselves: subscribers have locked in +245.8% total profit over the last six months (since inception!).

👉 Start your one-month trial now for just $10, and be ready for the next trade alert.